UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012
|
|
- Malcolm Merritt
- 5 years ago
- Views:
Transcription
1 Avonex Pen Interferon beta-1a Added as alternative dosing formulation for the treatment of multiple sclerosis. Prior Korlym Mifepristone Added as alternative agent to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Prior Pulmicort Inhaler Budesonide inhalation maintenance treatment of asthma. Symbicort Budesonide/formoterol maintenance treatment of asthma. Step therapy Cimzia Certolizumab pegol treatment rheumatoid arthritis and Crohn s disease. Prior authorization required. Available through Forteo Teriparatide treatment of osteoporosis. Prior Ranexa Ranolazine treatment of chronic angina. Step therapy Penlac Solution 8%* Ciclopirox Added as an alternative agent for treatment of mild to moderate onychomycosis of fingernails and toenails. Desenex Powder 2%* Miconazole topical powder treatment of tinea pedis, tinea corporis, tinea cruris, and tinea versicolor. Aclovate Cream and Ointment 0.05%* Alclometasone topical cream Temovate Gel and Cream 0.5%* Clobetasol topical gel and cream Derma-Smooth Oil/FS* Fluocinolone acetonide topical oil Locoid Solution, Cream, and Ointment 0.1%* Hydrocortisone butyrate topical solution, cream, and ointment Dermatop Cream and Prednicarbate topical cream Ointment 0.1%* Bleph 10 Ophthalmic Ointment* Optipranolol Ophthalmic Sol 0.3%* Dexasol Ophthalmic Sol 0.1%* FML Forte Opthalmic Sus 0.25%* Vasoclear Ophthalmic Sol 0.02%* Clear Eyes Redness Relief* Sulfacetamide Sodium 10% Metipranolol Ophthalmic Dexamethasone sodium phosphate Fluorometholone Naphazoline HCl Naphazoline-Glycerin treatment of conjunctivitis, corneal ulcer and other superficial infections. reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. treatment of allergic conjunctivitis and allergic marginal corneal ulcer. treatment of allergic conjunctivitis, ocular burns or trauma due to corneal injury, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. * Only Generics are covered Page 1 of 5
2 Vasoclear A Ophthalmic Naphazoline/Zinc sulfate Sol* 6/1/2012 7/1/2012 Visine-AC Ophthalmic Sol* Tetrahydrozoline/Zinc sulfate Muro 128 Ophthalmic Sol Sodium chloride hypertonic 5%* Victrelis Boceprevir Cyclocort 0.1% Cream Lokara Lotion 0.5% Topicort Cream and Gel 0.05%* Topicort Cream and Ointment 0.25%* Apexicon Cream and Ointment 0.05%* Amcinonide topical cream Desonide topical lotion Desoximetasone topical cream and gel Desoximetasone topical cream Diflorasone topical cream Westcort Ointment 0.2%* Hydrocortisone valerate topical ointment Betoptic-S Ophthalmic Susp 0.25%* Azopt Opthalmic Susp 1%* Betaxolol HCl Brinzolamide Viread Oral Powder and 150, 200, and 250 mg tablets Tenofovir 6/1/2012 7/1/2012 Prezista Darunavir 6/1/2012 7/1/2012 Jakafi Ruxolitinib 6/1/2012 7/1/2012 Inlyta Axitinib relief of redness of the eye due to minor irritations or relief of burning and irritation due to dryness of the eye or discomfort due to minor irritations. temporary relief of corneal edema. An alternative agent is available on the PDL including Incivek. Current users will be including desonide ointment and cream, alclometasone, fluocinolone, hydrocortisone, and triamcinolone. including betamethasone, fluocinolone, fluticasone cream, hydrocortisone acetate, hydrocortisone butyrate, mometasone, and triamcinolone. including timolol, levobunolol, carteolol, and metipranolol. including dorzolamide and dorzolamide/timolol. Added as alternative dosing formulations for the treatment of HIV infection in combination with other anti-retroviral agents. Added as alternative dosing formulations for the treatment of HIV infection in combination with other anti-retroviral agents. treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Prior treatment of advanced renal cell cancer after failure of 1 prior systemic therapy. Prior authorization required. Available through * Only Generics are covered Page 2 of 5
3 6/1/2012 7/1/2012 Erivedge Vismodegib Added as an alternative agent for treatment of metastatic basal cell carcinoma or in patients with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation. Prior authorization 6/1/2012 7/1/2012 Kalydeco Ivacaftor 6/1/2012 7/1/2012 Berinert C1 Inhibitor, Human treatment of cystic fibrosis (CF) in patients who have a G551D mutation in the CFTR gene. Prior authorization required. Available through treatment of acute abdominal or facial attacks of hereditary angioedema. Available through 6/1/2012 7/1/2012 Lipitor* Atorvastatin Added as an alternative agent as an adjunct to diet for the treatment of hypercholesterolemia or hyperlipoproteinemia. Step therapy 6/1/2012 7/1/2012 Xyzal* tablet Levocetirizine tablet treatment of allergic rhinitis. Step therapy 6/1/2012 7/1/2012 Nucynta ER Tapentadol ER treatment of chronic, moderate to severe pain that requires continuous, around-theclock opioid analgesia for an extended time period. Step therapy 6/1/2012 7/1/2012 Janumet XR Metformin/Sitagliptin treatment of type 2 diabetes mellitus. Step therapy 6/1/2012 7/1/2012 Xarelto Rivaroxaban Added as an alternative agent for deep venous thrombosis (DVT) prophylaxis in patients undergoing knee or hip replacement surgery and stroke and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation. Prior authorization required. 6/1/2012 7/1/2012 Abilify Aripiprazole Modification Step therapy 6/1/2012 7/1/2012 Seroquel XR Quetiapine ER including risperidone, olanzapine, ziprasidone, and quetiapine (immediate release formulation). Current users will be 6/1/2012 7/1/2012 Crestor Rosuvastatin including simvastatin, pravastatin, lovastatin, and atorvastatin. Current users will not be 6/1/2012 7/1/2012 Zovirax Ointment Acyclovir Alternative formulations and agents are available on the PDL including acyclovir tablet and valacyclovir tablet. Current prescriptions for the tablet formulation will be allowed to finish current therapy. 6/1/2012 7/1/2012 Allegra tablet* Fexofenadine tablet Alternatives agents are available on the PDL including loratadine, cetirizine, and levocetirizine. Current users will be Pegasys Proclick Peginterferon alfa-2a Androderm 2 mg and 4 mg patches Testosterone patch Firazyr Icatibant Added as an alternative dosing formulation for the treatment of chronic hepatitis C infection. Prior authorization required. Available through treatment of hypogonadism (primary or hypogonadotropic types). Prior authorization required. treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Available through specialty * Only Generics are covered Page 3 of 5
4 Onfi Clobazam Added as an alternative agent for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older. Step therapy Xalkori Crizotinib Zelboraf Vemurafenib treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Prior authorization required. Available through treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation. Prior authorization required. Available through Wellbutrin XL 150 mg and 300 mg* Bupropion ext release treatment of major depressive disorder and seasonal affective disorder. Uroxatral* Alfuzosin ER Accu-Chek Aviva Plus Test Strips Invega Sustenna Paliperidone inj Modification Risperdal Consta Risperidone inj Modification Carafate* Suspension Sucralfate Modification Suboxone Buprenorphine/naloxone Modification Subutex* Buprenorphine Modification Androgel 1% Testosterone gel Prozac 20 mg tablets Fluoxetine 20 mg tablets Suboxone tablets Buprenorphine/naloxone 2/1/2012 2/1/2012 Incivek Telaprevir 12/1/2011 1/1/2012 Androgel 1.62% Testosterone gel 12/1/2011 1/1/2012 Creon 3000 unit Pancrelipase 12/1/2011 1/1/2012 Lupron Depot 6- Month Leuprolide acetate treatment of benign prostatic hyperplasia. Added as an alternative test strip for blood glucose testing for patients with diabetes mellitus. Prior authorization required. Current users will be Prior authorization required. Current users will be Age edit Prior authorization required for patients aged 10 years of age up to 65 years of age. Current users will be Quantity limit remains the same (3 tabs per day 24 mg) for the initial 3 months of Alternative formulations are available on the PDL including Androgel 1.62% and Androderm. Current users will not be Alternative formulations of fluoxetine are available on the PDL including fluoxetine 10 and 20 mg capsules. Current users will not be grandfathered, and expected to transition to the capsule formulation. An alternative formulation is available on the PDL including Suboxone sublingual film. Current prescriptions for the tablet formulation will be allowed to finish current therapy. treatment of chronic hepatitis C infection (genotype 1) in adults with compensated liver disease. Prior authorization is treatment of hypogonadism (primary or hypogonadotropic types). Prior authorization is required. Added as an alternative dosage formulation for the treatment of pancreatic insufficiency. Added as an alternative dosing formulation for the treatment of advanced prostate cancer. Prior authorization is required. Available through * Only Generics are covered Page 4 of 5
5 12/1/2011 1/1/2012 Sylatron Peginterferon alfa-2b adjuvant treatment of malignant melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. Prior authorization is 12/1/2011 1/1/2012 Edurant Rilpivirine 12/1/2011 1/1/2012 Complera Emtricitabine/Rilpivirine/ Tenofovir 12/1/2011 1/1/2012 Victrelis Boceprevir 12/1/2011 1/1/2012 Potiga Exogabine treatment of antiretroviral treatment-naive adults with human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-naive adults. treatment of chronic hepatitis C infection (genotype 1) in adults with compensated liver disease. Prior authorization is adjunctive treatment of partial-onset seizures in patients aged 18 years and older. Step therapy 12/1/2011 1/1/2012 Zytiga Abiraterone treatment of metastatic castration-resistant prostate cancer in combination with prednisone in patients who have received prior chemotherapy containing docetaxel. Prior authorization is required. Available through 12/1/2011 1/1/2012 Mepron Atovaquone Modification Prior authorization is required. 12/1/2011 1/1/2012 Celexa* 40 mg Citalopram Modification Quantity limit changed to 1 tablet per day. Current users of greater than 40 mg will be 12/1/2011 1/1/2012 Gabitril Tiagabine Modification Minimum age edit implemented to reflect FDA approved age limitations. Prior authorization required for patients less than the FDA approved age limitations. Age edit modification only applies to new starts. Step therapy remains for patients above the age edit. 12/1/2011 1/1/2012 Vimpat Lacosamide Modification Minimum age edit implemented to reflect FDA approved age limitations. Prior authorization required for patients less than the FDA approved age limitations. Age edit modification only applies to new starts. Step therapy remains for patients above the age edit. 12/1/2011 1/1/2012 Keppra* tablet Levetiracetam Modification Step therapy removed. 12/1/2011 1/1/2012 Keppra* solution Levetiracetam Modification Step therapy removed. Maximum age edit of 10 years of age Patients 10 years of age and greater require prior authorization. 12/1/2011 1/1/2012 Trileptal* tablet Oxcarbazepine Modification Step therapy removed. 12/1/2011 1/1/2012 Trileptal* suspension Oxcarbazepine Modification Step therapy removed. Maximum age edit of 10 years of age Patients 10 years of age and greater require prior authorization. 10/14/ /14/2011 Vyvanse Lisdexamfetamine treatment of attention-deficit hyperactivity disorder (ADHD). Age edit * Only Generics are covered Page 5 of 5
UnitedHealthcare Community Plan PDL Modifications
Lialda Mesalamine Apriso Mesalamine treatment of ulcerative colitis. treatment of ulcerative colitis. Afinitor Disperz Everolimus treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis
More informationUnitedHealthcare Community Plan PDL Modifications
Lialda Mesalamine Apriso Mesalamine Afinitor Disperz Everolimus treatment of ulcerative colitis. treatment of ulcerative colitis. treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis
More informationMedicare Part D 2012 Formulary Changes Service To Senior and Total Fit
Medicare Part D 2012 Formulary s Service To Senior and Total Fit Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
More informationStep Therapy Criteria 2019
Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD
More informationBLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationALLERGIC RHINITIS-NASAL
ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More information2018 Step Therapy (ST) Criteria
2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationDrug Formulary Update, January 2017 Commercial and State Programs
Drug Formulary Update, January 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationGranite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE January 22, 2013 SUBJECT EFFECTIVE DATE January 15, 2013 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 15, 2013 Pharmacy Services Vincent D. Gordon, Deputy
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationQuarterly Pharmacy Formulary Change Notice
MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,
More informationANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY
South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the November 21, 2013 meeting of the Pharmacy
More informationDrugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional
Drugs approved from 1st January 2015 till present S.NO Name Of Drug Indication Date of 1 Levocetirizine ODS 2.5mg /5mg dosage form) For allergic rhinitis and chronic urticaria. 14.01.15 2 Decitabine Injection
More informationPHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT May 31, 2012
PHARMACY TIMES BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT May 31, 2012 We would like to inform you of the following changes to the 2012 IEHP Formulary that were approved by the Pharmacy and Therapeutics
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics
More informationStep Therapy Requirements. Effective: 03/01/2015
Effective: 03/01/2015 Updated 02/2015 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA OXTELLAR XR POTIGA QUDEXY
More informationNB Drug Plans Formulary Update
Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit
More informationWellCare of South Carolina Preferred Drug List Update
WellCare of South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on August 21,
More information2017 Step Therapy Criteria
FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.
More informationALLERGIC CONJUNCTIVITIS AGENTS
2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops
More informationStep Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)
CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG
More informationMercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationTennCare Program TN MAC Price Change List As of: 03/30/2017
1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017
More informationLIST OF DRUGS DURING 2004
LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 01/21/2015 Effective date: 02/21/2015 Therapeutic Classes reviewed: Allergen-Specific Immunotherapy
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationAcyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
More informationCRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 55 March 2012
Area Drug and Therapeutics Committee Prescribing Supplement No 55 In this issue Drugs reviewed by the SMC in February 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: February 15, 2018. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationTEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018
TEST Network Health Insurance Corporation NetworkCares Step Therapy Last Updated 11/2018 ANTICONVULSANT THERAPY Aptiom Banzel Briviact Celontin Dilantin 30 Mg Capsule Equetro Fycompa 0.5 Mg/ml Oral Susp
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationVNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom
More informationVNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017
Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA
More informationANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
More informationNeighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
More informationMichigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan
Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review
More informationABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More information1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
1/1/2019 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 1/1/19, Cigna is making changes to our formularies that may impact medication coverage for customers at your pharmacy. We have included a
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationStep Therapy Requirements
An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet
More informationPharmacy Benefit Coverage Updates Jan. 1, 2018
Pharmacy Benefit Coverage Updates Jan. 1, 2018 UnitedHealthcare routinely evaluates prescription benefit coverage to help ensure we offer members affordable and effective medication options. Medications
More informationMemorial Hermann Advantage HMO February 2019 Formulary Addendum
Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added
More informationMercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
More information2018 Step Therapy FID 18088
2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationAdapted from: Best Practices for Medication Management for Children & Adolescents in Foster Care. October 2015
Adapted from: Best Practices for Medication Management for Children & Adolescents in Foster Care October 2015 Psychotropic Medications Key Information Purpose: This document is designed for any reader
More informationTable 1: Price increases for Brand Name Drugs with Generic Equivalents
Table 1: Price increases for Brand Name Drugs with Generic Equivalents Brand Name Medication and Dose Total % Change Since 10/2012 ACTOS 15 MG TABLET 6.36 11.03 73.39% ACTOS 30 MG TABLET 9.7 16.80 73.23%
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationWellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.
More informationPHARMA-MEDIC SERVICES INC. POLICY MANUAL
PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationFORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
More informationBULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015
BULLETIN # 84 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 22, 2015 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
More informationComparison of representative topical corticosteroid preparations (classified according to the US system)
Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationAmitriptyline Hydrochloride Heart Health & BP Amlodipine Besylate 5mg Norvasc Antibiotics Amoxicillin 500 mg Amoxil
Antiviral Acyclovir 400mg Zovirax Asthma Advair Diskus Diskus 250/50 Fluticasone/Salmeterol Asthma Albuterol Sulfate 2.5 mg/3 ml Proventil Arthritis and Pain Allendronate Sodium 70 mg Fosamax Arthritis
More informationStep Therapy Requirements
Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet
More informationFORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationSecretary for Health and Family Services Selections for Preferred Products
Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based
More informationHEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016
Selected 2016 Highlights Epidemiologic research on chronic kidney disease and fistula patency, solid and hematologic malignancies Health economics and outcomes research on beta3-agonist treatment for overactive
More informationAmitriptyline Hydrochloride Heart Health & BP Amlodipine Besylate 5mg Norvasc Antibiotics Amoxicillin 500 mg Amoxil
School Corp Formulary Antiviral Acyclovir 400mg Zovirax Asthma Advair Diskus Diskus 250/50 Fluticasone/Salmeterol Asthma Albuterol Sulfate 2.5 mg/3 ml Proventil Arthritis and Pain Allendronate Sodium 70
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION
More informationProduct List Finished Dosage Forms (FDF) B2B Business
Product List 2017 Finished Dosage Forms (FDF) B2B Business Anaesthetics Dermatology Lidocaine Lidocaine and Prilocaine Dexmedetomidine Hydrochloride Anti-Infectives Amoxicillin Trihydrate and Potassium
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationHealth Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
More informationSTEP THERAPY PROGRAM
STEP THERAPY PROGRAM Step Therapy Program Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. For these drugs, Great-West s Special Authorization
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationEffective for all members on August 1, 2017
August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List
More informationPrescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)
This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)
More informationWellCare s South Carolina Preferred Drug List Update
WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/03/2015.
More informationBlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
More informationPharmacy Policy Updates-Medicare Advantage
Pharmacy Policy Updates-Medicare Advantage The following recommendations included on this update have been approved by the Pharmacy and Therapeutics Committee. Please note: For Medicare Advantage plans
More informationFirstCarolinaCare Insurance Company. Step Therapy Requirements
FirstCarolinaCare Insurance Company Step Therapy Requirements Effective: 12/01/2018 ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION
More informationANTICONVULSANT THERAPY
Network Health Insurance Corporation NetworkCares Step Therapy Last Updated: 7/2017 ANTICONVULSANT THERAPY Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200
More informationVNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019
VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED
More informationSanta Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E
Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET
More informationAMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1 ANTICONVULSANTS
More information